HSPA7 and familial pancreatic carcinoma: So far, two recent articles pointed out that the m6A-modified pseudogene HSPA7 could be a new immunotherapy target for GBM patients 34, and aberrant m6A modification of the pseudogene WTAPP1 results in increased translation of its protein-coding counterpart to promote pancreatic cancer progression 35.